Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, Texas.
Department of Anesthesiology and Perioperative Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Anesthesiology. 2023 Dec 1;139(6):880-898. doi: 10.1097/ALN.0000000000004734.
Acute kidney injury (AKI) is a common complication in cardiac surgery patients, with a reported incidence of 20 to 30%. The development of AKI is associated with worse short- and long-term mortality, and longer hospital length of stay. The pathogenesis of cardiac surgery-associated AKI is poorly understood but likely involves an interplay between preoperative comorbidities and perioperative stressors. AKI is commonly diagnosed by using increases in serum creatinine or decreased urine output and staged using a standardized definition such as the Kidney Disease Improving Global Outcomes classification. Novel biomarkers under investigation may provide earlier detection and better prediction of AKI, enabling mitigating therapies early in the perioperative period. Recent clinical trials of cardiac surgery patients have demonstrated the benefit of goal-directed oxygen delivery, avoidance of hyperthermic perfusion and specific fluid and medication strategies. This review article highlights both advances and limitations regarding the prevention, prediction, and treatment of cardiac surgery-associated AKI.
急性肾损伤(AKI)是心脏手术患者的常见并发症,其发病率为 20%至 30%。AKI 的发展与更差的短期和长期死亡率以及更长的住院时间相关。心脏手术相关 AKI 的发病机制尚不清楚,但可能涉及术前合并症和围手术期应激因素之间的相互作用。AKI 通常通过血清肌酐升高或尿量减少来诊断,并使用标准化定义(如肾脏病改善全球结局分类)进行分期。正在研究的新型生物标志物可能提供 AKI 的早期检测和更好的预测,从而在围手术期早期实施缓解治疗。最近对心脏手术患者的临床试验表明,目标导向性氧输送、避免高热灌注以及特定液体和药物策略的获益。本文综述了心脏手术相关 AKI 的预防、预测和治疗方面的进展和局限性。